MediWound to Present at 11th Annual Wells Fargo Healthcare Conference

YAVNE, Israel, Aug. 26, 2016 -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 11^th Annual Wells Fargo Securities Healthcare Conference taking place from September 7-8, 2016 in Boston. Gal Cohen, President and Chief Executive Officer, will deliver MediWound’s presentation on Wednesday, September 7th at 9:20 a.m. Eastern time.

Mr. Cohen’s presentation will be webcast live on the internet and can be accessed by visiting the Investor Relations section of the Company’s website at www.mediwound.com. A replay of the webcast will be archived on the MediWound website for 90 days following the presentation.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid^®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe, Israel and Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue.

MediWound's second innovative product, EscharEx^®, is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx contains the same proteolytic enzyme technology as NexoBrid, and benefits from the wealth of existing development data on NexoBrid.  In two Phase 2 studies, EscharEx demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. 

For more information, please visit www.mediwound.com.